精氨酸加压素缺乏患者的骨折风险:一项全国性匹配队列研究
基于韩国国民健康保险服务数据库(2003-2020年)的全国性匹配队列研究,纳入3497例年龄≥50岁的精氨酸加压素缺乏(AVP-D)患者及1:1匹配对照,评估主要骨质疏松性骨折、椎体骨折、非椎体骨折和髋部骨折风险。调整混杂因素后,男性AVP-D患者上述骨折风险与对照相当;女性AVP-D患者主要骨质疏松性骨折、椎体骨折或非椎体骨折风险与对照无差异,但髋部骨折风险显著升高(HR 1.83;95% CI 1.06-3.17)。
要点
- 女性AVP-D患者髋部骨折风险显著高于对照(HR 1.83;95% CI 1.06-3.17)。
- 男性AVP-D患者主要骨质疏松性骨折、椎体骨折、非椎体骨折和髋部骨折风险与对照相当。
- 年龄、女性、既往骨折史和类固醇使用与AVP-D患者高骨折风险相关。
核心结论
- 与对照相比,仅女性AVP-D患者表现出显著升高的髋部骨折风险。
- 这些发现强调了对女性AVP-D患者进行长期随访、针对性筛查和积极管理髋部骨折风险的必要性。
研究设计与样本
- 研究使用韩国国民健康保险服务数据库(2003-2020年)的数据。
- 共纳入3497例年龄≥50岁诊断为AVP-D的患者(2111例男性,1386例女性),以及基于年龄、性别、索引年份和关键合并症(包括糖尿病、高血压、心血管疾病和脑血管疾病)1:1匹配的对照。
- 采用Cox比例风险模型估计主要骨质疏松性骨折、椎体骨折、非椎体骨折和髋部骨折的风险比(HR)及95%置信区间(CI)。
主要发现
- 调整包括收入状况、类固醇使用和既往骨折史在内的混杂因素后,男性AVP-D患者的主要骨质疏松性骨折、椎体骨折、非椎体骨折和髋部骨折风险与对照相当。
- 女性AVP-D患者的主要骨质疏松性骨折、椎体骨折或非椎体骨折风险与对照无差异,但髋部骨折风险显著更高(HR 1.83;95% CI 1.06-3.17)。
- 年龄、女性、既往骨折史和类固醇使用与AVP-D患者高骨折风险相关。
临床怎么用
- 作者认为,这些发现强调了对女性AVP-D患者进行长期随访、针对性筛查和积极管理髋部骨折风险的必要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Arginine vasopressin deficiency (AVP-D) might increase fracture risk. This nationwide cohort study found a significantly increased hip fracture risk in female AVP-D patients ≥ 50 years, but not in males. These findings highlight sex-specific vulnerability, urging focused fracture prevention in female AVP-D patients. PURPOSE: Arginine vasopressin deficiency (AVP-D) is associated with various complications and increased mortality. However, its association with long-term fracture risk remains unclear. We aimed to assess fracture risks in patients aged 50 years or older with AVP-D. METHODS: We used data from the Korea National Health Insurance Service database (2003-2020). A total of 3,497 patients aged ≥ 50 years diagnosed with AVP-D (2,111 men and 1,386 women) were included, along with 1:1 matched controls, based on age, sex, index year, and key comorbidities, including diabetes mellitus, hypertension, cardiovascular disease, and cerebrovascular disease. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of major osteoporotic fractures (MOFs), vertebral fractures (VFs), non-vertebral fractures (non-VFs), and hip fractures (HFs). RESULTS: After adjusting for confounding factors, including income status, steroid use, and prior fracture history, the risk for MOFs, VFs, non-VFs, and HFs in male patients with AVP-D were comparable to those in controls. In women with AVP-D, the risk of MOFs, VFs, or non-VFs was not different from controls, but the risk of HFs was significantly higher (HR 1.83; 95% CI, 1.06-3.17). Age, female, previous history of fracture, and steroid use contributed to high risk for fracture in patients with AVP-D. CONCLUSION: Compared with controls, only female patients with AVP-D demonstrated a significantly increased risk of HFs. These findings highlight the need for long-term follow-up, targeted screening, and proactive management of HF risk in female patients with AVP-D.
引用
- Park SS, Jeong H, Ahn CH, et al. Fracture risks in patients with arginine vasopressin deficiency: a nationwide matched cohort study. Osteoporos Int. 2026. PMID: 41603925. doi:10.1007/s00198-026-07849-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。